A recent study showed that rates of antiretroviral therapy in enrollees living with HIV increased over the years, but women ...

Merck & Co Inc (NYSE:MRK) revealed topline results from two pivotal Phase 3 trials of a two-drug regimen of ...

On the occasion of World AIDS Day on 1 December 2024, the International Antiviral (formerly AIDS) Society-USA (IAS-USA) has ...

Merck's experimental two-drug combination met the main goal of significantly suppressing replication of the HIV-1 virus in ...

Antiretrovirals are necessary to delay disease progression but the undesirable side effects often affect the patient’s ...

However, the combination of Merck's approved doravirine and investigational islatravir didn't prove superiority over Gilead's ...